Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

Results of a Pulmonologist Survey Regarding Knowledge and Practices With Inhalation Devices for COPD.

Braman SS, Carlin BW, Hanania NA, Mahler DA, Ohar JA, Pinto-Plata V, Shah T, Eubanks D, Dhand R.

Respir Care. 2018 Jul;63(7):840-848. doi: 10.4187/respcare.05717. Epub 2018 May 1.

PMID:
29717099
2.

Results of a Patient Survey Regarding COPD Knowledge, Treatment Experiences, and Practices With Inhalation Devices.

Dhand R, Mahler DA, Carlin BW, Hanania NA, Ohar JA, Pinto-Plata V, Shah T, Eubanks D, Braman SS.

Respir Care. 2018 Jul;63(7):833-839. doi: 10.4187/respcare.05715. Epub 2018 Mar 20.

PMID:
29559537
3.

Peak Inspiratory Flow Rate in Chronic Obstructive Pulmonary Disease: Implications for Dry Powder Inhalers.

Ghosh S, Ohar JA, Drummond MB.

J Aerosol Med Pulm Drug Deliv. 2017 Dec;30(6):381-387. doi: 10.1089/jamp.2017.1416. Epub 2017 Sep 21. Review.

PMID:
28933581
4.

Personalization of Device Therapy - Prime Time for Peak Inspiratory Flow Rate.

Loh CH, Ohar JA.

Chronic Obstr Pulm Dis. 2017 Jul 14;4(3):172-176. doi: 10.15326/jcopdf.4.3.2017.0155. No abstract available.

5.

Guiding Principles for the Use of Nebulized Long-Acting Beta2-Agonists in Patients with COPD: An Expert Panel Consensus.

Wise RA, Acevedo RA, Anzueto AR, Hanania NA, Martinez FJ, Ohar JA, Tashkin DP.

Chronic Obstr Pulm Dis. 2016 Nov 15;4(1):7-20. doi: 10.15326/jcopdf.4.1.2016.0141.

6.

Medicare Bundled Payments for Care Improvement Initiative for Chronic Obstructive Pulmonary Disease Readmissions: A Negative Study That Has Positive Implications.

Ohar JA.

Ann Am Thorac Soc. 2017 May;14(5):617-618. doi: 10.1513/AnnalsATS.201701-011ED. No abstract available.

PMID:
28459621
7.

Suboptimal Inspiratory Flow Rates Are Associated with Chronic Obstructive Pulmonary Disease and All-Cause Readmissions.

Loh CH, Peters SP, Lovings TM, Ohar JA.

Ann Am Thorac Soc. 2017 Aug;14(8):1305-1311. doi: 10.1513/AnnalsATS.201611-903OC.

PMID:
28406710
8.

A retrospective study of two populations to test a simple rule for spirometry.

Ohar JA, Yawn BP, Ruppel GL, Donohue JF.

BMC Fam Pract. 2016 Jun 4;17:65. doi: 10.1186/s12875-016-0467-2.

9.

Dual therapy strategies for COPD: the scientific rationale for LAMA + LABA.

Cohen JS, Miles MC, Donohue JF, Ohar JA.

Int J Chron Obstruct Pulmon Dis. 2016 Apr 15;11:785-97. doi: 10.2147/COPD.S54513. eCollection 2016. Review.

10.

Gender and asthma-chronic obstructive pulmonary disease overlap syndrome.

Wheaton AG, Pleasants RA, Croft JB, Ohar JA, Heidari K, Mannino DM, Liu Y, Strange C.

J Asthma. 2016 Sep;53(7):720-31. doi: 10.3109/02770903.2016.1154072. Epub 2016 Apr 6.

11.

Characteristics and Prevalence of Asthma/Chronic Obstructive Pulmonary Disease Overlap in the United States.

Kumbhare S, Pleasants R, Ohar JA, Strange C.

Ann Am Thorac Soc. 2016 Jun;13(6):803-10. doi: 10.1513/AnnalsATS.201508-554OC.

PMID:
26974689
12.

Germline BAP1 Mutational Landscape of Asbestos-Exposed Malignant Mesothelioma Patients with Family History of Cancer.

Ohar JA, Cheung M, Talarchek J, Howard SE, Howard TD, Hesdorffer M, Peng H, Rauscher FJ, Testa JR.

Cancer Res. 2016 Jan 15;76(2):206-15. doi: 10.1158/0008-5472.CAN-15-0295. Epub 2015 Dec 30. Erratum in: Cancer Res. 2018 Jan 1;78(1):309. Cancer Res. 2017 Jun 1;77(11):3124.

13.

Germline BAP1 mutation in a family with high incidence of multiple primary cancers and a potential gene-environment interaction.

Cheung M, Kadariya Y, Talarchek J, Pei J, Ohar JA, Kayaleh OR, Testa JR.

Cancer Lett. 2015 Dec 28;369(2):261-5. doi: 10.1016/j.canlet.2015.09.011. Epub 2015 Sep 26.

14.

Risks May Not Be Reasons for COPD Readmissions.

Ohar JA.

Ann Am Thorac Soc. 2015 Sep;12(9):1259-60. doi: 10.1513/AnnalsATS.201507-444ED. No abstract available.

PMID:
26372799
15.

Targeting Persons With or At High Risk for Chronic Obstructive Pulmonary Disease by State-based Surveillance.

Pleasants RA, Heidari K, Wheaton AG, Ohar JA, Strange C, Croft JB, Liao W, Mannino DM, Kraft M.

COPD. 2015;12(6):680-9. doi: 10.3109/15412555.2015.1043424. Epub 2015 Sep 14.

16.

Smoking duration, respiratory symptoms, and COPD in adults aged ≥45 years with a smoking history.

Liu Y, Pleasants RA, Croft JB, Wheaton AG, Heidari K, Malarcher AM, Ohar JA, Kraft M, Mannino DM, Strange C.

Int J Chron Obstruct Pulmon Dis. 2015 Jul 21;10:1409-16. doi: 10.2147/COPD.S82259. eCollection 2015.

17.

Changing pattern in malignant mesothelioma survival.

Faig J, Howard S, Levine EA, Casselman G, Hesdorffer M, Ohar JA.

Transl Oncol. 2015 Feb;8(1):35-9. doi: 10.1016/j.tranon.2014.12.002.

18.

Umeclidinium/vilanterol combination inhaler efficacy and potential impact on current chronic obstructive pulmonary disease management guidelines.

Davidson JF, Donohue JF, Ohar JA.

Expert Opin Drug Saf. 2015 Feb;14(2):317-24. doi: 10.1517/14740338.2015.983898. Review.

PMID:
25598422
19.

Review of drug safety and efficacy of arformoterol in chronic obstructive pulmonary disease.

Loh CH, Donohue JF, Ohar JA.

Expert Opin Drug Saf. 2015 Mar;14(3):463-72. doi: 10.1517/14740338.2015.998196. Epub 2015 Jan 7. Review.

PMID:
25563342
20.

Fluticasone propionate/salmeterol 250/50 μg versus salmeterol 50 μg after chronic obstructive pulmonary disease exacerbation.

Ohar JA, Crater GD, Emmett A, Ferro TJ, Morris AN, Raphiou I, Sriram PS, Dransfield MT.

Respir Res. 2014 Sep 24;15:105. doi: 10.1186/s12931-014-0105-2.

21.

Chronic obstructive pulmonary disease and asthma-patient characteristics and health impairment.

Pleasants RA, Ohar JA, Croft JB, Liu Y, Kraft M, Mannino DM, Donohue JF, Herrick HL.

COPD. 2014 Jun;11(3):256-66. doi: 10.3109/15412555.2013.840571. Epub 2013 Oct 23.

PMID:
24152212
22.

Nebulized arformoterol: what is its place in the management of COPD?

Miles MC, Donohue JF, Ohar JA.

Ther Adv Respir Dis. 2013 Apr;7(2):81-6. doi: 10.1177/1753465812465784. Epub 2012 Nov 12. Review.

PMID:
23147985
23.

Optimum bronchodilator combinations in chronic obstructive pulmonary disease: what is the current evidence?

Miles MC, Donohue JF, Ohar JA.

Drugs. 2012 Feb 12;72(3):301-8. doi: 10.2165/11598580-000000000-00000. Review.

PMID:
22316346
24.

Mono- and combination therapy of long-acting bronchodilators and inhaled corticosteroids in advanced COPD.

Ohar JA, Donohue JF.

Semin Respir Crit Care Med. 2010 Jun;31(3):321-33. doi: 10.1055/s-0030-1254072. Epub 2010 May 21. Review.

PMID:
20496301
25.

Do symptoms predict COPD in smokers?

Ohar JA, Sadeghnejad A, Meyers DA, Donohue JF, Bleecker ER.

Chest. 2010 Jun;137(6):1345-53. doi: 10.1378/chest.09-2681. Epub 2010 Apr 2.

26.

Health-related quality of life and chronic obstructive pulmonary disease in North Carolina.

Brown DW, Pleasants R, Ohar JA, Kraft M, Donohue JF, Mannino DM, Liao W, Herrick H.

N Am J Med Sci. 2010 Feb;2(2):60-5. doi: 10.4297/najms.2010.260.

27.

COPD is associated with a macrophage scavenger receptor-1 gene sequence variation.

Ohar JA, Hamilton RF Jr, Zheng S, Sadeghnejad A, Sterling DA, Xu J, Meyers DA, Bleecker ER, Holian A.

Chest. 2010 May;137(5):1098-107. doi: 10.1378/chest.09-1655. Epub 2010 Jan 15.

28.

Adam33 polymorphisms are associated with COPD and lung function in long-term tobacco smokers.

Sadeghnejad A, Ohar JA, Zheng SL, Sterling DA, Hawkins GA, Meyers DA, Bleecker ER.

Respir Res. 2009 Mar 12;10:21. doi: 10.1186/1465-9921-10-21.

29.

IL13 promoter polymorphism 1112C/T modulates the adverse effect of tobacco smoking on lung function.

Sadeghnejad A, Meyers DA, Bottai M, Sterling DA, Bleecker ER, Ohar JA.

Am J Respir Crit Care Med. 2007 Oct 15;176(8):748-52. Epub 2007 Jul 5.

PMID:
17615386
30.

Identification of a mesothelioma phenotype.

Ohar JA, Ampleford EJ, Howard SE, Sterling DA.

Respir Med. 2007 Mar;101(3):503-9. Epub 2006 Aug 21. Erratum in: Respir Med. 2008 Dec;102(12):1844.

31.

Effects of corticosteroids on lung function in asthma and chronic obstructive pulmonary disease.

Donohue JF, Ohar JA.

Proc Am Thorac Soc. 2004;1(3):152-60. Review.

PMID:
16113428
32.

Prevention of venous thromboembolic disease following primary total knee arthroplasty. A randomized, multicenter, open-label, parallel-group comparison of enoxaparin and warfarin.

Fitzgerald RH Jr, Spiro TE, Trowbridge AA, Gardiner GA Jr, Whitsett TL, O'Connell MB, Ohar JA, Young TR; Enoxaparin Clinical Trial Group.

J Bone Joint Surg Am. 2001 Jun;83-A(6):900-6.

PMID:
11407799
33.

New combination therapies for asthma.

Donohue JF, Ohar JA.

Curr Opin Pulm Med. 2001 Mar;7(2):62-8. Review.

PMID:
11224725
34.

Computerized morphometry of the pulmonary vasculature over a range of intravascular pressures.

Ohar JA, Waller KS, Williams TJ, Luke DA, Demello DE.

Anat Rec. 1998 Sep;252(1):92-101.

PMID:
9737746
35.

Increased gelatinolytic activity in bronchoalveolar lavage fluid in stable lung transplant recipients.

Trello CA, Williams DA, Keller CA, Crim C, Webster RO, Ohar JA.

Am J Respir Crit Care Med. 1997 Dec;156(6):1978-86.

PMID:
9412583
36.

Effects of aerosolized surfactant in patients with stable chronic bronchitis: a prospective randomized controlled trial.

Anzueto A, Jubran A, Ohar JA, Piquette CA, Rennard SI, Colice G, Pattishall EN, Barrett J, Engle M, Perret KA, Rubin BK.

JAMA. 1997 Nov 5;278(17):1426-31.

PMID:
9356001
37.

Flow cytometric analysis of lung lymphocytes in lung transplant recipients.

Crim C, Keller CA, Dunphy CH, Maluf HM, Ohar JA.

Am J Respir Crit Care Med. 1996 Mar;153(3):1041-6.

PMID:
8630543
39.

Chronic platelet-activating factor induces a decrease in pulmonary vascular compliance, hydroxyproline, and loss of vascular matrix.

Ohar JA, Waller KS, Pantano J, Demello DE, Dahms TE.

Am J Respir Crit Care Med. 1994 Jun;149(6):1628-34.

PMID:
8004322
40.

IR-192, low dose rate endobronchial brachytherapy in the treatment of malignant airway obstruction.

Raju PI, Roy T, McDonald RD, Harrison BR, Crim C, Hyers TM, Marshall SJ, Ohar JA, Naunheim KS.

Int J Radiat Oncol Biol Phys. 1993 Oct 20;27(3):677-80.

PMID:
8226164
41.
42.

Bronchoalveolar lavage cell count and differential are not reliable indicators of amiodarone-induced pneumonitis.

Ohar JA, Jackson F, Dettenmeier PA, Bedrossian CW, Tricomi SM, Evans RG.

Chest. 1992 Oct;102(4):999-1004.

PMID:
1395816
43.
44.

A rabbit model of pulmonary hypertension induced by the synthetic platelet-activating factor acetylglyceryl ether phosphorylcholine.

Ohar JA, Pyle JA, Waller KS, Hyers TM, Webster RO, Lagunoff D.

Am Rev Respir Dis. 1990 Jan;141(1):104-10.

PMID:
2297169
45.

Usefulness of serial pulmonary function testing as an indicator of amiodarone toxicity.

Ohar JA, Jackson F Jr, Redd RM, Evans GR, Bedrossian CW.

Am J Cardiol. 1989 Dec 1;64(19):1322-6.

PMID:
2589198

Supplemental Content

Support Center